HRP20110369T1 - Vektor za učinkovit odabir i/ili sazrijevanje protutijela i njegove upotrebe - Google Patents
Vektor za učinkovit odabir i/ili sazrijevanje protutijela i njegove upotrebe Download PDFInfo
- Publication number
- HRP20110369T1 HRP20110369T1 HR20110369T HRP20110369T HRP20110369T1 HR P20110369 T1 HRP20110369 T1 HR P20110369T1 HR 20110369 T HR20110369 T HR 20110369T HR P20110369 T HRP20110369 T HR P20110369T HR P20110369 T1 HRP20110369 T1 HR P20110369T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- vector
- recombinant antibody
- sequence
- maturation
- Prior art date
Links
- 230000035800 maturation Effects 0.000 title claims 4
- 238000000034 method Methods 0.000 claims abstract 2
- 108091026890 Coding region Proteins 0.000 claims 3
- 210000000628 antibody-producing cell Anatomy 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108020005038 Terminator Codon Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000002823 phage display Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Indexing, Searching, Synchronizing, And The Amount Of Synchronization Travel Of Record Carriers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05028501A EP1803814A1 (en) | 2005-12-27 | 2005-12-27 | Method of improving the antibody selection capacity in phage-display library |
| PCT/IT2006/000876 WO2007074496A2 (en) | 2005-12-27 | 2006-12-27 | Vector for efficient selection and/or maturation of an antibody and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110369T1 true HRP20110369T1 (hr) | 2011-06-30 |
Family
ID=36177357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110369T HRP20110369T1 (hr) | 2005-12-27 | 2011-05-18 | Vektor za učinkovit odabir i/ili sazrijevanje protutijela i njegove upotrebe |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | USRE45968E1 (ja) |
| EP (2) | EP1803814A1 (ja) |
| JP (1) | JP5435956B2 (ja) |
| AT (1) | ATE506435T1 (ja) |
| AU (1) | AU2006329517B2 (ja) |
| CA (1) | CA2634962C (ja) |
| CY (1) | CY1111505T1 (ja) |
| DE (1) | DE602006021476D1 (ja) |
| DK (1) | DK1966375T3 (ja) |
| ES (1) | ES2362120T3 (ja) |
| HR (1) | HRP20110369T1 (ja) |
| IL (1) | IL191633A (ja) |
| PL (1) | PL1966375T3 (ja) |
| PT (1) | PT1966375E (ja) |
| RS (1) | RS51866B (ja) |
| SI (1) | SI1966375T1 (ja) |
| WO (1) | WO2007074496A2 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
| WO2009109572A2 (en) * | 2008-03-03 | 2009-09-11 | Ablynx Nv | Monovalent phage display of single variable domains |
| WO2013115425A1 (en) * | 2012-01-31 | 2013-08-08 | Scripps Korea Antibody Institute | Methods for screening an antibody by one-cycle panning |
| WO2014096672A1 (fr) | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| MA56416A (fr) | 2015-05-12 | 2022-05-04 | Regeneron Pharma | Détermination de la pureté de protéines multimériques |
| AR106991A1 (es) | 2015-12-15 | 2018-03-07 | Gilead Sciences Inc | Anticuerpos neutralizantes del virus de inmunodeficiencia humana |
| JP7083820B2 (ja) | 2016-09-30 | 2022-06-13 | セントレ ナショナル デ ラ レセルシュ シャンティフィク | 膜マーカー |
| EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| CN111196857B (zh) * | 2020-02-05 | 2023-07-21 | 杭州贤至生物科技有限公司 | 一种新型冠状病毒多表位重组抗原及其制备方法 |
| KR20230007470A (ko) * | 2020-05-06 | 2023-01-12 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Sars-cov-2 s 단백질에 결합하는 중화 항체 |
| US20230416343A1 (en) * | 2020-08-07 | 2023-12-28 | Sorrento Therapeutics, Inc. | Neutralizing Antibodies that Bind the SARS-COV-2 S Protein |
| WO2022053188A1 (en) | 2020-09-11 | 2022-03-17 | Alfasigma S.P.A. | NOVEL DNA SEQUENCES ENCODING HUMAN SCFVs ANTIBODIES WITH NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2 AND USES THEREOF |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663684A (en) * | 1970-06-01 | 1972-05-16 | Hoffmann La Roche | Carcinoembryonic antigen and diagnostic method using radioactive iodine |
| DE69032284T2 (de) | 1989-03-21 | 1998-10-08 | Vical, Inc., San Diego, Calif. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH0482266A (ja) * | 1990-07-24 | 1992-03-16 | Seiko Epson Corp | 半導体装置、及びその製造方法 |
| ES2330052T3 (es) * | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
| ES2341666T3 (es) * | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
| CA2340335A1 (en) * | 1998-08-20 | 2000-03-02 | Cell Genesys, Inc. | Use of suppressor trna's to regulate cytotoxicity during the production of recombinant gene products |
| CA2286301A1 (en) | 1999-11-01 | 2001-05-01 | Michael Bruce Zwick | The filamentous phage as a multivalent scaffold for coupling synthetic peptides for immunization |
| JP2003514824A (ja) * | 1999-11-15 | 2003-04-22 | ビオミラ，インコーポレーテッド | 合成脂質−ａ類似体およびその使用 |
| TW513852B (en) | 2002-01-21 | 2002-12-11 | Nat Chung Cheng Univerity | Multiphase oscillator and multiphase oscillation signal generating method |
| US20040151724A1 (en) * | 2002-10-31 | 2004-08-05 | Julia Coronella-Wood | Antibody fab fragments specific for breast cancer |
| AU2005250369A1 (en) * | 2004-05-18 | 2005-12-15 | Genentech, Inc. | M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein |
| EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
| JP5905457B2 (ja) | 2010-07-02 | 2016-04-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 尿路感染症（ｕｔｉ）ワクチン |
-
2005
- 2005-12-27 EP EP05028501A patent/EP1803814A1/en not_active Withdrawn
-
2006
- 2006-12-27 AU AU2006329517A patent/AU2006329517B2/en not_active Ceased
- 2006-12-27 EP EP06842807A patent/EP1966375B1/en active Active
- 2006-12-27 WO PCT/IT2006/000876 patent/WO2007074496A2/en active Application Filing
- 2006-12-27 PL PL06842807T patent/PL1966375T3/pl unknown
- 2006-12-27 ES ES06842807T patent/ES2362120T3/es active Active
- 2006-12-27 AT AT06842807T patent/ATE506435T1/de active
- 2006-12-27 PT PT06842807T patent/PT1966375E/pt unknown
- 2006-12-27 US US13/831,258 patent/USRE45968E1/en active Active
- 2006-12-27 RS RS20110218A patent/RS51866B/en unknown
- 2006-12-27 SI SI200631020T patent/SI1966375T1/sl unknown
- 2006-12-27 CA CA2634962A patent/CA2634962C/en active Active
- 2006-12-27 US US12/097,876 patent/US8003383B2/en not_active Ceased
- 2006-12-27 JP JP2008548090A patent/JP5435956B2/ja active Active
- 2006-12-27 DE DE602006021476T patent/DE602006021476D1/de active Active
- 2006-12-27 DK DK06842807.7T patent/DK1966375T3/da active
-
2008
- 2008-05-22 IL IL191633A patent/IL191633A/en active IP Right Grant
-
2011
- 2011-05-18 HR HR20110369T patent/HRP20110369T1/hr unknown
- 2011-05-27 CY CY20111100518T patent/CY1111505T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL191633A (en) | 2012-04-30 |
| PL1966375T3 (pl) | 2011-08-31 |
| ATE506435T1 (de) | 2011-05-15 |
| CA2634962C (en) | 2015-03-31 |
| RS51866B (en) | 2012-02-29 |
| AU2006329517A1 (en) | 2007-07-05 |
| WO2007074496A3 (en) | 2008-01-10 |
| US20080286274A1 (en) | 2008-11-20 |
| SI1966375T1 (sl) | 2011-07-29 |
| CA2634962A1 (en) | 2007-07-05 |
| US8003383B2 (en) | 2011-08-23 |
| EP1803814A1 (en) | 2007-07-04 |
| CY1111505T1 (el) | 2015-08-05 |
| EP1966375A2 (en) | 2008-09-10 |
| AU2006329517B2 (en) | 2012-09-06 |
| DK1966375T3 (da) | 2011-06-20 |
| DE602006021476D1 (de) | 2011-06-01 |
| IL191633A0 (en) | 2008-12-29 |
| EP1966375B1 (en) | 2011-04-20 |
| ES2362120T3 (es) | 2011-06-28 |
| JP5435956B2 (ja) | 2014-03-05 |
| JP2009521241A (ja) | 2009-06-04 |
| WO2007074496A2 (en) | 2007-07-05 |
| USRE45968E1 (en) | 2016-04-12 |
| PT1966375E (pt) | 2011-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110369T1 (hr) | Vektor za učinkovit odabir i/ili sazrijevanje protutijela i njegove upotrebe | |
| HK1150856A1 (en) | Il-17 homologous polypeptide and therapeutic uses thereof il-17 | |
| JP2005253469A5 (ja) | ||
| RU2012106148A (ru) | Вариантные формы уратоксидазы и их применение | |
| TW200732472A (en) | Method for the recombinant expression of a polypeptide | |
| JP2005120106A5 (ja) | ||
| HRP20150659T1 (hr) | Domaä†inski soj bakterija koji sadrži mutirani spr gen te ima smanjenu tsp aktivnost | |
| WO2020125120A1 (zh) | 一种抗体文库的构建方法及其应用 | |
| WO2005033316A3 (de) | Sekretion von proteinen aus hefen | |
| HRP20211748T1 (hr) | Postupci i sastavi za sekreciju heterolognih polipeptida | |
| US9890216B2 (en) | Antibodies with engineered IgG Fc domains | |
| JP2008505626A5 (ja) | ||
| DE602005020972D1 (en) | Rhamnosepromotor-expressionssystem | |
| IL150676A0 (en) | NOVEL STRa6 POLYPEPTIDES | |
| US20230332175A1 (en) | Transgenic rabbit with common light chain | |
| WO2006042719A3 (de) | Polypeptid mit phytaseaktivität und dieses codierende nucleotidsequenz | |
| NZ503316A (en) | Polypeptide and nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis | |
| JP2010279373A5 (ja) | ||
| US9803207B2 (en) | Expression vector for production of recombinant proteins in prokaryotic host cells | |
| BR0111265A (pt) | Bacteriocina antilisteria | |
| JPH06509947A (ja) | キメラ抗ｃｅａ抗体 | |
| EP0393045A1 (en) | Fv antibody fragment production | |
| Wang et al. | Production and characterization of a novel antimicrobial peptide HKABF by Pichia pastoris | |
| CN115992159A (zh) | 一种获得目标蛋白的方法、融合蛋白、载体及应用 | |
| JP2006516655A5 (ja) |